VEGFR-1/FLT-1 Polyclonal antibody

VEGFR-1/FLT-1 Polyclonal Antibody for WB, IP, IF, IHC, ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat and More (1)





Cat no : 13687-1-AP


FLT, FLT 1, FLT1, FLT-1, Fms like tyrosine kinase 1, FRT, sflt1, Tyrosine protein kinase FRT, VEGF receptor 1, VEGFR 1, VEGFR1, VEGFR-1, VEGFR-1/FLT-1

Tested Applications

Positive WB detected inHEK-293 cells, human placenta tissue, mouse lung tissue
Positive IP detected inA549 cells
Positive IHC detected inhuman renal cell carcinoma tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells

Recommended dilution

Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:1000-1:4000
Immunofluorescence (IF)IF : 1:10-1:100
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

13687-1-AP targets VEGFR-1/FLT-1 in WB, IP, IF, IHC, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman, mouse, rat, Deer
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen VEGFR-1/FLT-1 fusion protein Ag4558
Full Name fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
Calculated Molecular Weight 1338 aa, 151 kDa
Observed Molecular Weight 55-60 kDa
GenBank Accession NumberBC039007
Gene Symbol VEGFR-1/FLT-1
Gene ID (NCBI) 2321
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Vascular endothelial growth factor receptor-1 (VEGFR-1, FLT-1) is a receptor tyrosine kinase belonging to the VEGFR family. VEGF is a key regulator of physiological angiogenesis and has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by VEGFR-1 and VEGFR-2. Both the two receptors have seven immunoglobulin-like repeats in the extracellular domain, a single transmembrane region and a tyrosine kinase domain. VEGFR-1 binds VEGFA, PIGF and VEGFB, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Two isoforms of VEGFR-1 exist, a full-length transmembrane form and a short souble form (sVEGFR-1) consisting of only the extracellular ligand-binding domain. (PMID: 12778165; 17109193; 8806634)


Product Specific Protocols
WB protocol for VEGFR-1/FLT-1 antibody 13687-1-APDownload protocol
IHC protocol for VEGFR-1/FLT-1 antibody 13687-1-APDownload protocol
IF protocol for VEGFR-1/FLT-1 antibody 13687-1-APDownload protocol
IP protocol for VEGFR-1/FLT-1 antibody 13687-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



ACS Appl Mater Interfaces

Biocompatible Chitin Hydrogel Incorporated with PEDOT Nanoparticles for Peripheral Nerve Repair.

Authors - Lin Huang


Statins Prevent the Deleterious Consequences of Placental Chemerin Upregulation in Preeclampsia

Authors - Lunbo Tan

Biomed Pharmacother

Lychee seed polyphenol ameliorates DR via inhibiting inflammasome/apoptosis and angiogenesis in hRECs and db/db mice

Authors - Xiao-Hong Xiang

Stem Cells

Heparanase released from mesenchymal stem cells activates integrin beta1/HIF-2alpha/Flk-1 signaling and promotes endothelial cell migration and angiogenesis.

Authors - Xinyang Hu

J Ethnopharmacol

Diterpenoid tanshinones inhibit gastric cancer angiogenesis through the PI3K/Akt/mTOR signaling pathway

Authors - Jie-Ru Yu

Clin Sci (Lond)

Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.

Authors - Mengqiu Wu